Advertisement

HPV vaccination

Published:December 12, 2017DOI:https://doi.org/10.1016/j.ygyno.2017.11.037
      Since the introduction of the human papillomavirus (HPV) vaccine in 2006, the evidence regarding its efficacy and safety has continued to highlight its importance in cancer prevention. Despite the clear benefits of vaccination, patient perception, public health policy, and changing vaccine availability have impacted vaccine uptake in the United States. Moreover, the vaccination landscape has changed dramatically over the last several years due in large part to the release of a nine-valent HPV (9vHPV) vaccine in 2014, revisions to ACIP guidelines for vaccine dosing, and changes in state-level policies. While overall rates of uptake in eligible populations have increased over the last several years, they still remain low relative to other adolescent vaccines [
      • Walker T.Y.
      • Elam-Evans L.D.
      • Singleton J.A.
      • et al.
      National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years — United States, 2016.
      ]. As a result, there have been major initiatives and calls to action to increase HPV vaccination by the Centers for Disease Control and Prevention (CDC), the National Cancer Institute, the American Society of Clinical Oncology [
      • Bailey H.H.
      • Chuang L.T.
      • duPont N.C.
      • et al.
      American Society of Clinical Oncology statement: human papillomavirus vaccination for cancer prevention.
      ], the American Cancer Society and the President's Cancer Panel.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Walker T.Y.
        • Elam-Evans L.D.
        • Singleton J.A.
        • et al.
        National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years — United States, 2016.
        MMWR Morb. Mortal. Wkly Rep. 2017; 66: 874-882
        • Bailey H.H.
        • Chuang L.T.
        • duPont N.C.
        • et al.
        American Society of Clinical Oncology statement: human papillomavirus vaccination for cancer prevention.
        J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016; 34: 1803-1812
        • Kjaer S.K.
        • Nygård M.
        • Dillner J.
        • et al.
        A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries.
        Clin. Infect. Dis. 2017; : cix797
        • Huh W.K.
        • Joura E.A.
        • Giuliano A.R.
        • et al.
        Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial.
        Lancet. 2017; 390: 2143-2159
        • Joura E.A.
        • Giuliano A.R.
        • Iversen O.-E.
        • et al.
        A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
        N. Engl. J. Med. 2015; 372: 711-723
        • Moreira E.D.
        • Block S.L.
        • Ferris D.
        • et al.
        Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials.
        Pediatrics. 2016; 138
        • GlaxoSmithKline
        GSKDirect Cervarix TIP-LOK syringe discontinuation.
        • Hough-Telford C.
        • Kimberlin D.W.
        • Aban I.
        • et al.
        Vaccine delays, refusals, and patient dismissals: a survey of pediatricians.
        Pediatrics. 2016; 138: 1-9
        • Hildesheim A.
        • Gonzalez P.
        • Kreimer A.R.
        • et al.
        Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
        Am. J. Obstet. Gynecol. 2016; 215: 212.e211-212.e215
        • Kreimer A.R.
        • Struyf F.
        • Del Rosario-Raymundo M.R.
        • et al.
        Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials.
        Lancet Oncol. 2015; 16: 775-786
        • Sankaranarayanan R.
        • Prabhu P.R.
        • Pawlita M.
        • et al.
        Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
        Lancet Oncol. 2016; 17: 67-77
        • Dobson S.R.
        • McNeil S.
        • Dionne M.
        • et al.
        Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
        JAMA. 2013; 309
        • Iversen O.E.
        • Miranda M.J.
        • Ulied A.
        • et al.
        Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women.
        JAMA. 2016; 316: 2411-2421
        • Meites E.
        • Kempe A.
        • Markowitz L.
        Use of a 2-dose schedule for human papillomavirus vaccination — updated recommendations of the Advisory Committee on Immunization Practices.
        MMWR Morb. Mortal. Wkly Rep. 2016; 65 (2016): 1405-1408
        • Oliver S.E.
        • Unger E.R.
        • Lewis R.
        • et al.
        Prevalence of human papillomavirus among females after vaccine introduction—National Health and Nutrition Examination Survey, United States, 2003–2014.
        J. Infect. Dis. 2017; 216: 594-603
        • Flagg E.W.
        • Torrone E.A.
        • Weinstock H.
        Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007–2014.
        Am. J. Public Health. 2016; 106: 2211-2218
        • Howell-Jones R.
        • Soldan K.
        • Wetten S.
        • et al.
        Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study.
        J. Infect. Dis. 2013; 208: 1397-1403
        • Mesher D.
        • Soldan K.
        • Howell-Jones R.
        • et al.
        Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England.
        Vaccine. 2013; 32: 26-32
        • Bollerup S.
        • Baldur-Felskov B.
        • Blomberg M.
        • Baandrup L.
        • Dehlendorff C.
        • Kjaer S.K.
        Significant reduction in the incidence of genital warts in young men 5 years into the Danish human papillomavirus vaccination program for girls and women.
        Sex. Transm. Dis. 2016; 43: 238-242
        • Brotherton J.M.
        • Fridman M.
        • May C.L.
        • Chappell G.
        • Saville A.M.
        • Gertig D.M.
        Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.
        Lancet. 2011; 377
        • Drolet M.
        • Bénard É.
        • Boily M.-C.
        • et al.
        Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
        Lancet Infect. Dis. 2015; 15: 565-580
        • Gertig D.M.
        • Brotherton J.M.L.
        • Budd A.C.
        • Drennan K.
        • Chappell G.
        • Saville A.M.
        Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
        BMC Med. 2013; 11: 1-12
        • Kavanagh K.
        • Pollock K.G.
        • Potts A.
        • et al.
        Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types.
        Br. J. Cancer. 2014; 110: 2804-2811
        • Miller K.
        • Dilley S.E.
        • Huh W.K.
        Lessons learned from domestic and international human papillomavirus vaccination programs: a review.
        Am. J. Obstet. Gynecol. 2017; (in press)
        • Brotherton J.M.L.
        Could one dose of bivalent HPV vaccine prevent cervical cancer?.
        Lancet Oncol. 2015; 16: 739-740
        • Giorgi Rossi P.
        • Carozzi F.
        • Federici A.
        • Ronco G.
        • Zappa M.
        • Franceschi S.
        Cervical cancer screening in women vaccinated against human papillomavirus infection: recommendations from a consensus conference.
        Prev. Med. 2017; 98: 21-30